Children’s Tumor Foundation President Annette Bakker was recently published in Newsweek, writing about the speed and the collaborative spirit by which the scientific community is working together to find treatments and vaccines for Covid-19. With this collaboration in mind, Annette writes about the NF community experience (Synodos, NFPC) that led to the FDA approval of Koselugo (selumetinib), the first-ever approved drug for neurofibromatosis, and calls for more of this spirited collaboration, urgency, and funding across all diseases. Click here to read the article.
